Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 8/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.58 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.51 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433330 | 0.92 | CXCR4 (0.64) | CXCR4IL23R | |
| SCHEMBL30646312 | 0.89 | KISS1R (0.65) | KISS1RCXCR4CXCL8 | |
| SCHEMBL38652302 | 0.89 | CXCR4 (0.59) | KISS1RCXCR4DPP3 | |
| SCHEMBL29416065 | 0.89 | KISS1R (0.65) | KISS1RCXCR4CXCL8 | |
| SCHEMBL29350708 | 0.89 | DPP3 (0.64) | KISS1RCXCR4DPP3IL23R | |
| SCHEMBL31409436 | 0.88 | CXCR4 (0.63) | KISS1RCXCR4CXCL8IL23RMAPK8 | |
| SCHEMBL31409438 | 0.88 | CXCR4 (0.63) | KISS1RCXCR4CXCL8IL23RMAPK8 | |
| SCHEMBL30288110 | 0.88 | KISS1R (0.61) | KISS1RCXCR4DPP3 | |
| SCHEMBL31433347 | 0.88 | KISS1R (0.56) | KISS1RCXCR4DPP3IL23RMAPK8 | |
| SCHEMBL31452905 | 0.87 | CXCR4 (0.62) | KISS1RCXCR4IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | KISS1R 1078/4885CXCR4 429/4885DPP3 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.